Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX), backed by significant analyst-implied upside, ranks among the overlooked penny stocks to buy right now. An expanding radiopharmaceutical pipeline, now stretching into a new brain tumor indication, is strengthening the company’s long-term growth narrative.
On July 1, 2026, Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) updated its corporate presentation to highlight progress across its 212Pb-based radiopharmaceutical pipeline and its integrated manufacturing strategy. The update emphasized the company’s theranostic approach targeting solid tumors with next-generation alpha therapies, along with plans to expand its addressable market through regional daily production and direct-to-hospital delivery. The presentation provided material related to multiple ongoing Phase 1/2a trials, including VMT-α-NET for SSTR2-positive neuroendocrine tumors, VMT01 for melanoma, and PSV359 for FAP-α-expressing solid tumors, with early data pointing to deepening and durable responses, favorable safety and tolerability, and improved tumor retention.
That update followed news on June 3, 2026, that Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) dosed the first meningioma patient with [212Pb]VMT-α-NET in its ongoing Phase 1/2a study. The new cohort is designed to evaluate safety, dosimetry and preliminary anti-tumor activity in meningioma, expanding the company’s strategy of testing VMT-α-NET across somatostatin receptor subtype 2 (SSTR2)-expressing tumor types beyond neuroendocrine tumors. Meningiomas represent roughly 40% of primary central nervous system tumors diagnosed annually in the United States, and consistently express SSTR2, supporting their role as a target for this class of therapy.
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) is a clinical-stage radiopharmaceutical company developing targeted alpha-particle therapies (TATs) for cancer using the isotope Pb-212. Its theranostic approach combines imaging (Pb-203) with therapy (Pb-212) to deliver targeted radiation directly to tumors, minimizing damage to healthy tissue, with active trials for neuroendocrine tumors and melanoma.
While we acknowledge the risk and potential of CATX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than CATX and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. Follow Insider Monkey on Google News.
